Ascendiant Capital Markets Estimates VVOS Q1 Earnings

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – Analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for Vivos Therapeutics in a research report issued on Thursday, June 4th. Ascendiant Capital Markets analyst L. Ward anticipates that the company will post earnings per share of ($0.57) for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $3.10 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.39) per share. Ascendiant Capital Markets also issued estimates for Vivos Therapeutics’ Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.53) EPS and Q4 2027 earnings at ($0.53) EPS.

A number of other equities analysts have also weighed in on VVOS. HC Wainwright lowered their target price on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vivos Therapeutics has an average rating of “Hold” and an average target price of $2.80.

Vivos Therapeutics Price Performance

Shares of NASDAQ VVOS opened at $0.70 on Wednesday. The firm has a market cap of $9.73 million, a P/E ratio of -0.33 and a beta of 6.10. The company has a current ratio of 0.27, a quick ratio of 0.27 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a 1-year low of $0.55 and a 1-year high of $7.95. The business’s 50 day moving average is $0.88 and its 200-day moving average is $1.47.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The firm had revenue of $5.14 million for the quarter, compared to the consensus estimate of $4.35 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.

Institutional Investors Weigh In On Vivos Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Connective Capital Management LLC acquired a new stake in Vivos Therapeutics during the third quarter worth approximately $620,000. DRW Securities LLC boosted its holdings in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Vivos Therapeutics in the 2nd quarter valued at $220,000. XTX Topco Ltd acquired a new stake in shares of Vivos Therapeutics in the 2nd quarter valued at $65,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Vivos Therapeutics in the 1st quarter valued at $28,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Insider Transactions at Vivos Therapeutics

In related news, major shareholder Michael C. Skaff purchased 1,353,625 shares of Vivos Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the transaction, the insider directly owned 1,353,625 shares of the company’s stock, valued at $1,813,857.50. This represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.10% of the stock is owned by corporate insiders.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.